Eye Half-face.jpg
RGen_Product_Image_1.png

Retinal Laser for
RPE Cell Regeneration

R:GEN® AND CORE TECHNOLOGY

 
patient.png
RGen Logo.png
R:GEN®

Innovative Laser Solution for Common Retinal Diseases

  • Selective Retina Therapy

  • 527 nm wavelength & 1.7 µs pulse duration

  • Ramping Technology

  • Real Time Feedback Technology

RTF Sensor (Disposable)

The RTF sensor enables selective retinal treatment by detecting the pressure wave of microbubble generated after irradiation with R:GEN laser.

Core Technology.jpg
Ideal Wavelength and Pulse Duration (527 nm / 1.7 μs)

The R:GEN with 527 nm wavelength and 1.7 μs pulse width is ideal for selectively damaging RPE cells while sparing other retinal tissues.

Ideal Wavelength.jpg

Ref. JOURNAL OF THE OPTICAL SOCIETY OF AMERICA, VOL. 60, NO. 2

Bull. Soc. Belge Ophtalmol 302 (2006): 51-69.

Ramping Technology

Rapidly produce 15 laser pulses with ramping up energies to check the optimal pulses for patient.

Ramping Technology.jpg

Ref. Kim MK, et al. Graefes Arch Clin Exp Ophthalmol. 2018 Sep;256(9):1639-1651; High Resolution Imaging in Microscopy and Ophthalmology: New Frontiers in Biomedical Optics [Internet]. Cham (CH): Springer; 2019. Chapter 11.

Real-time Feedback Technology

R:GEN utilizes optoacoustic and reflectometry to ensure the appropriate treatment energy. Real-Time Feedback technology detects sound wave & back scattering light from RPE microbubbles generated by laser and irradiation automatically stops when microbubble formation is detected.

Reflectometry.jpg
Optoacoustic.jpg
 

R:GEN MECHANISM OF ACTION

How R:GEN works

When problematic RPE cells are treated by R:GEN®, the irradiated RPE cells are destroyed without damaging
neighbor photoreceptors. Subsequently, RPE cell regeneration is induced which results in improvement of the retinal metabolism.

MoA.jpg
RPE Regeneration

RPE layer was recovered with RPE cell migration and regeneration.

RPE Generation.jpg

Ref. Invest Ophthalmol Vis Sci. 2016 Jun 1;57(7):3486-95.

 

REGULATORY STATUS

EU.png
CE Marking
  • Dry Age-related Macular Degeneration (AMD)

  • Central Serous Chorioretinopathy (CSC)

  • Diabetic Macular Edema (DME)

USA.png
FDA Approval
  • Clinically Significant Macular Edema (CSME)